Open access
Aug 2026
Rigosertib Reverses Hypertrophic Cardiomyopathy in Noonan Syndrome
It is suggested rigosertib normalizes and reverses RASopathy-associated HCM and other NS-associated syndromic features, supporting its development as a promising treatment for RAF1-associated HCM and, potentially, other RASopathy-dependent pathologies.
Levi Legler, K. Marchetti, Bing Xu et al.
· Circulation · 0 citations